Dropping two drug candidates puts Genmab in a better position, says CEO

Genmab made a rare move during Q3 by scrapping two candidates. However, neither CEO Jan van de Winkel nor a Sydbank analyst think the decision will have much of an impact on the company's future.

CEO of Genmab Jan van de Winkel | Photo: PR/Genmab

It isn't every day that biotech company Genmab has to abandon a drug under development.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs